Research Reports Initiation on Medical Laboratories Stocks -- Cancer Genetics, Exact Sciences, HTG Molecular Diagnostics, and BioTelemetry

Tuesday, May 16, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 16, 2017 /PRNewswire/ -- has issued research reports on the following Medical Laboratories

and Research companies: Cancer Genetics Inc. (NASDAQ: CGIX), Exact Sciences Corp. (NASDAQ: EXAS), HTG Molecular Diagnostics Inc. (NASDAQ: HTGM), and BioTelemetry Inc. (NASDAQ: BEAT). The Research, Testing, and Medical Laboratories sector includes a range
of activities from highly, research oriented companies working to develop and commercialize new drug discovery/delivery systems and gene and cell therapies, to more service oriented firms engaged in medical and other biosciences-testing services. Learn more about these stocks by downloading their free report at:

Cancer Genetics  

On Monday, shares in New Jersey-based Cancer Genetics Inc. (CGIX) recorded a trading volume of 197,500 shares. The stock ended the session 4.58% higher at $4.00. The Company's shares have gained 14.29% in the last one month, 70.21% over the previous three months, and 196.30% on an YTD basis. The stock is trading 14.27% above its 50-day moving average and 77.67% above its 200-day moving average. Moreover, shares of Cancer Genetics, which develops, commercializes, and provides molecular and biomarker-based tests and services in the US, India, and China, have a Relative Strength Index (RSI) of 53.52.

On May 15th, 2017, CGIX announced that it has partnered with Ventana Medical Systems, Inc., a member of the Roche Group (Roche), to enable rapid patient access to testing following the FDA's recent approval of the Roche's VENTANA PD-L1 (SP263) Assay. The agreement ensures that CGIX is one of the first laboratories in the U.S. with pathologists trained to use and interpret the VENTANA PD-L1 (SP263) test to help inform patient-treatment decisions. The free research report on CGIX is available at:

Exact Sciences  

Wisconsin headquartered Exact Sciences Corp.'s stock closed the day 3.97% lower at $32.43. A total volume of 18.79 million shares was traded, which was above their three months average volume of 3.02 million shares. The Company's shares have advanced 39.36% in the past month, 74.07% in the previous three months, and 142.74% since the start of this year. The stock is trading 30.08% and 64.98% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have an RSI of 64.65.

On April 17th, 2017, research firm Leerink Partners initiated an 'Outperform' rating on the Company's stock, with a target price of $30 per share.

On May 01st, 2017, Exact Sciences announced that the Company will participate in the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas on Tuesday, May 16th, 2017. Kevin Conroy, Chairman and CEO, and Jeff Elliott, CFO, will participate in a fireside chat at the conference at 11:20 a.m. PT. A live webcast of the event will be available on the Company's website. The complimentary report on EXAS can be downloaded at:

HTG Molecular Diagnostics  

Shares in Arizona-based HTG Molecular Diagnostics Inc. recorded a trading volume of 1.14 million shares. The stock ended yesterday's trading session 4.00% higher at $4.16. The Company's shares have advanced 116.67% in the previous three months and 85.71% on an YTD basis. The stock is trading above its 200-day moving average by 45.92%. Furthermore, shares of HTG Molecular Diagnostics, which develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling, have an RSI of 46.92.

On May 04th, 2017, HTG Molecular Diagnostics announced that its new HTG EdgeSeq PATH Assay is expected to be available for research uses by the end of the second quarter of 2017. The HTG EdgeSeq PATH Assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded sample availability is limited. Visit us today and download our complete research report on HTGM for free at:


Pennsylvania headquartered BioTelemetry Inc.'s stock finished Monday's session 0.53% higher at $28.30. A total volume of 561,006 shares was traded, which was above their three months average volume of 515,750 shares. The Company's shares have advanced 18.66% over the previous three months and 26.62% since the start of this year. The stock is trading above its 200-day moving average by 24.61%. Additionally, shares of BioTelemetry, which provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services, have an RSI of 41.33.

On May 10th, 2017, BioTelemetry announced the start of the main offer period of the tender offer to acquire all of the shares of LifeWatch AG. The main offer period is scheduled to expire at 4:00 p.m. CEST on May 23rd, 2017. LifeWatch's Board of Directors has announced that it fully supports the public tender offer, and has recommended that shareholders accept it and tender their shares accordingly. Get free access to your technical report on BEAT at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store